Serum Clusterin Level Could Reflect the Current Activity of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

We investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-specific indices. Fifty-seven patients with AAV and 40 healthy controls were included in this study. AAV-specific indices included the Short-Form 36-Item He...

Full description

Saved in:
Bibliographic Details
Published inYonsei medical journal Vol. 62; no. 11; pp. 1016 - 1022
Main Authors Yoon, Taejun, Ahn, Sung Soo, Pyo, Jung Yoon, Song, Jason Jungsik, Park, Yong-Beom, Lee, Sang-Won
Format Journal Article
LanguageEnglish
Published Korea (South) Yonsei University College of Medicine 01.11.2021
연세대학교의과대학
Subjects
Online AccessGet full text
ISSN0513-5796
1976-2437
1976-2437
DOI10.3349/ymj.2021.62.11.1016

Cover

Abstract We investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-specific indices. Fifty-seven patients with AAV and 40 healthy controls were included in this study. AAV-specific indices included the Short-Form 36-Item Health Survey Physical and Mental Component Summaries (SF-36 PCS and MCS) scores, Birmingham vasculitis activity score (BVAS), five-factor score (FFS), and vasculitis damage index. Clinical and laboratory data and AAV-specific indices were obtained at blood collection. The highest tertile of BVAS (≥16) was defined as high activity of AAV. The median age of AAV patients was 64.0 years and 19 patients were male. SF-36 PCS score (r=0.328), SF-36 MCS score (r=0.289), BVAS (r=-0.404), erythrocyte sedimentation rate (r=-0.336), and C-reactive protein levels (r=-0.421) were significantly correlated with serum clusterin levels. In the multivariable linear regression analysis using AAV-specific indices and serum clusterin levels, both FFS (β=0.412) and serum clusterin levels (β=-0.250) were significantly associated with BVAS. When the optimal serum clusterin cut-off level for high activity of AAV was identified as 130.45 µg/mL, patients with serum clusterin level ≤130.45 µg/mL had a significantly higher risk for high activity of AAV than did those without (relative risk 7.194). Patients with AAV exhibited significantly lower serum clusterin levels than did healthy controls (168.2 µg/mL vs. 230.5 µg/mL). Serum clusterin levels could reflect the current disease activity in patients with AAV.
AbstractList We investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-specific indices.PURPOSEWe investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-specific indices.Fifty-seven patients with AAV and 40 healthy controls were included in this study. AAV-specific indices included the Short-Form 36-Item Health Survey Physical and Mental Component Summaries (SF-36 PCS and MCS) scores, Birmingham vasculitis activity score (BVAS), five-factor score (FFS), and vasculitis damage index. Clinical and laboratory data and AAV-specific indices were obtained at blood collection. The highest tertile of BVAS (≥16) was defined as high activity of AAV.MATERIALS AND METHODSFifty-seven patients with AAV and 40 healthy controls were included in this study. AAV-specific indices included the Short-Form 36-Item Health Survey Physical and Mental Component Summaries (SF-36 PCS and MCS) scores, Birmingham vasculitis activity score (BVAS), five-factor score (FFS), and vasculitis damage index. Clinical and laboratory data and AAV-specific indices were obtained at blood collection. The highest tertile of BVAS (≥16) was defined as high activity of AAV.The median age of AAV patients was 64.0 years and 19 patients were male. SF-36 PCS score (r=0.328), SF-36 MCS score (r=0.289), BVAS (r=-0.404), erythrocyte sedimentation rate (r=-0.336), and C-reactive protein levels (r=-0.421) were significantly correlated with serum clusterin levels. In the multivariable linear regression analysis using AAV-specific indices and serum clusterin levels, both FFS (β=0.412) and serum clusterin levels (β=-0.250) were significantly associated with BVAS. When the optimal serum clusterin cut-off level for high activity of AAV was identified as 130.45 µg/mL, patients with serum clusterin level ≤130.45 µg/mL had a significantly higher risk for high activity of AAV than did those without (relative risk 7.194). Patients with AAV exhibited significantly lower serum clusterin levels than did healthy controls (168.2 µg/mL vs. 230.5 µg/mL).RESULTSThe median age of AAV patients was 64.0 years and 19 patients were male. SF-36 PCS score (r=0.328), SF-36 MCS score (r=0.289), BVAS (r=-0.404), erythrocyte sedimentation rate (r=-0.336), and C-reactive protein levels (r=-0.421) were significantly correlated with serum clusterin levels. In the multivariable linear regression analysis using AAV-specific indices and serum clusterin levels, both FFS (β=0.412) and serum clusterin levels (β=-0.250) were significantly associated with BVAS. When the optimal serum clusterin cut-off level for high activity of AAV was identified as 130.45 µg/mL, patients with serum clusterin level ≤130.45 µg/mL had a significantly higher risk for high activity of AAV than did those without (relative risk 7.194). Patients with AAV exhibited significantly lower serum clusterin levels than did healthy controls (168.2 µg/mL vs. 230.5 µg/mL).Serum clusterin levels could reflect the current disease activity in patients with AAV.CONCLUSIONSerum clusterin levels could reflect the current disease activity in patients with AAV.
We investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-specific indices. Fifty-seven patients with AAV and 40 healthy controls were included in this study. AAV-specific indices included the Short-Form 36-Item Health Survey Physical and Mental Component Summaries (SF-36 PCS and MCS) scores, Birmingham vasculitis activity score (BVAS), five-factor score (FFS), and vasculitis damage index. Clinical and laboratory data and AAV-specific indices were obtained at blood collection. The highest tertile of BVAS (≥16) was defined as high activity of AAV. The median age of AAV patients was 64.0 years and 19 patients were male. SF-36 PCS score (r=0.328), SF-36 MCS score (r=0.289), BVAS (r=-0.404), erythrocyte sedimentation rate (r=-0.336), and C-reactive protein levels (r=-0.421) were significantly correlated with serum clusterin levels. In the multivariable linear regression analysis using AAV-specific indices and serum clusterin levels, both FFS (β=0.412) and serum clusterin levels (β=-0.250) were significantly associated with BVAS. When the optimal serum clusterin cut-off level for high activity of AAV was identified as 130.45 µg/mL, patients with serum clusterin level ≤130.45 µg/mL had a significantly higher risk for high activity of AAV than did those without (relative risk 7.194). Patients with AAV exhibited significantly lower serum clusterin levels than did healthy controls (168.2 µg/mL vs. 230.5 µg/mL). Serum clusterin levels could reflect the current disease activity in patients with AAV.
Purpose: We investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-specific indices. Materials and Methods: Fifty-seven patients with AAV and 40 healthy controls were included in this study. AAV-specific indices included the Short-Form 36-Item Health Survey Physical and Mental Component Summaries (SF-36 PCS and MCS) scores, Birmingham vasculitis activity score (BVAS), five-factor score (FFS), and vasculitis damage index. Clinical and laboratory data and AAV-specific indices were obtained at blood collection. The highest tertile of BVAS (≥16) was defined as high activity of AAV. Results: The median age of AAV patients was 64.0 years and 19 patients were male. SF-36 PCS score (r=0.328), SF-36 MCS score (r=0.289), BVAS (r=-0.404), erythrocyte sedimentation rate (r=-0.336), and C-reactive protein levels (r=-0.421) were significantly correlated with serum clusterin levels. In the multivariable linear regression analysis using AAV-specific indices and serum clusterin levels, both FFS (β=0.412) and serum clusterin levels (β=-0.250) were significantly associated with BVAS. When the optimal serum clusterin cut-off level for high activity of AAV was identified as 130.45 μg/mL, patients with serum clusterin level ≤130.45μg/mL had a significantly higher risk for high activity of AAV than did those without (relative risk 7.194). Patients with AAV exhibited significantly lower serum clusterin levels than did healthy controls (168.2 μg/mL vs. 230.5 μg/mL). Conclusion: Serum clusterin levels could reflect the current disease activity in patients with AAV. KCI Citation Count: 0
Author Yoon, Taejun
Pyo, Jung Yoon
Lee, Sang-Won
Song, Jason Jungsik
Ahn, Sung Soo
Park, Yong-Beom
AuthorAffiliation 1 Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Korea
3 Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea
2 Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
AuthorAffiliation_xml – name: 3 Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea
– name: 1 Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Korea
– name: 2 Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Author_xml – sequence: 1
  givenname: Taejun
  orcidid: 0000-0003-2147-3555
  surname: Yoon
  fullname: Yoon, Taejun
  organization: Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Korea
– sequence: 2
  givenname: Sung Soo
  orcidid: 0000-0002-9002-9880
  surname: Ahn
  fullname: Ahn, Sung Soo
  organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
– sequence: 3
  givenname: Jung Yoon
  orcidid: 0000-0002-1866-6885
  surname: Pyo
  fullname: Pyo, Jung Yoon
  organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
– sequence: 4
  givenname: Jason Jungsik
  orcidid: 0000-0003-0662-7704
  surname: Song
  fullname: Song, Jason Jungsik
  organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea., Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea
– sequence: 5
  givenname: Yong-Beom
  orcidid: 0000-0003-4695-8620
  surname: Park
  fullname: Park, Yong-Beom
  organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea., Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea
– sequence: 6
  givenname: Sang-Won
  orcidid: 0000-0002-8038-3341
  surname: Lee
  fullname: Lee, Sang-Won
  organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea., Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34672135$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002766533$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9kk9v1DAQxS1URLeFT4CEcoRDgv8ksX1BiqJCK62EVApXK3EmrFsnXmxnpXx7kt0WFQ6c5jDv955G8y7Q2ehGQOgtwRljufw4D_cZxZRkJc0IyQgm5Qu0IZKXKc0ZP0MbXBCWFlyW5-gihHuMKSeYvkLnLC85JazYoOkb-GlIajuFCN6MyRYOYJPaTbZLbqG3oGMSd5DUk_cwxqTS0RxMnBPXJ9UYzQhT9G6_Mws0R7e3TRiMPq5a181pFYLTponQJT-aoCdrogmv0cu-sQHePM5L9P3z1V19nW6_frmpq22qcyZj2grNO01byHvBRcEAuq4AzWXbEip4KQinLSnannadhFKKnErgjHNMGlIIwi7Rh5Pv6Hv1oI1yjTnOn049eFXd3t0oKTgtMV60n07a_dQO0OnlWN9YtfdmaPx8JP_ejGa3-ByUKHKa89Xg_aOBd78mCFENJmiwthnBTUHRQuRcSoHLRfruedafkKe_LAJ5EmjvQvDQK21iE41bo41VBKu1A2rpgFo7oEqqCFFrBxaW_cM-2f-P-g15prgJ
CitedBy_id crossref_primary_10_3389_fimmu_2023_1103097
crossref_primary_10_1002_jcla_24543
crossref_primary_10_4078_jrd_2022_0002
Cites_doi 10.4049/jimmunol.177.9.6471
10.1136/ard.2006.054593
10.1136/ard.2008.101279
10.1620/tjem.203.189
10.2174/138945006777435317
10.2147/CMAR.S196273
10.1016/S0065-230X(09)04008-1
10.1002/art.37715
10.1097/MD.0b013e318205a4c6
10.1681/ASN.V351172
10.3349/ymj.2019.60.8.705
10.1007/s11926-012-0291-1
10.1016/j.bone.2018.02.018
10.1046/j.1365-2567.2003.01608.x
10.1016/j.biopha.2020.111174
10.1681/ASN.2016111179
10.1681/ASN.2016060690
10.1038/nrneph.2017.37
10.1136/annrheumdis-2012-201981
10.1111/imcb.12405
10.1038/nrrheum.2014.103
10.1056/NEJMoa0909905
ContentType Journal Article
Copyright Copyright: Yonsei University College of Medicine 2021.
Copyright: Yonsei University College of Medicine 2021 2021 Yonsei University College of Medicine
Copyright_xml – notice: Copyright: Yonsei University College of Medicine 2021.
– notice: Copyright: Yonsei University College of Medicine 2021 2021 Yonsei University College of Medicine
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
DOI 10.3349/ymj.2021.62.11.1016
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1976-2437
EndPage 1022
ExternalDocumentID oai_kci_go_kr_ARTI_9872600
PMC8542470
34672135
10_3349_ymj_2021_62_11_1016
Genre Journal Article
GrantInformation_xml – fundername: Yonsei University College of Medicine
  grantid: 6-2019-0184
– fundername: Korea Health Industry Development Institute
  grantid: HI14C1324
– fundername: ;
  grantid: HI14C1324
– fundername: ;
  grantid: 6-2019-0184
GroupedDBID ---
.55
.GJ
123
29R
2WC
36B
5-W
53G
5RE
8JR
8XY
9ZL
AAYXX
ACYCR
ADBBV
ADRAZ
AEGXH
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
CS3
DIK
DU5
E3Z
EBD
EF.
EMB
EMOBN
F5P
GROUPED_DOAJ
GX1
HYE
KQ8
L7B
M48
MK0
O5R
O5S
OK1
OVT
P2P
PGMZT
RNS
RPM
SV3
TR2
X7M
XSB
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c439t-b8c7dc2be4f87853eedd5ec79bb128768172b15bf2dd9e698429e737701a15813
IEDL.DBID M48
ISSN 0513-5796
1976-2437
IngestDate Sun Mar 09 07:52:46 EDT 2025
Thu Aug 21 14:11:13 EDT 2025
Fri Jul 11 09:16:50 EDT 2025
Thu Apr 03 07:07:32 EDT 2025
Thu Apr 24 23:06:44 EDT 2025
Tue Jul 01 04:03:23 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords current
activity
antineutrophil cytoplasmic antibody
vasculitis
Clusterin
Language English
License Copyright: Yonsei University College of Medicine 2021.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c439t-b8c7dc2be4f87853eedd5ec79bb128768172b15bf2dd9e698429e737701a15813
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Taejun Yoon and Sung Soo Ahn contributed equally to this work.
https://www.eymj.org/DOIx.php?id=10.3349/ymj.2021.62.11.1016
ORCID 0000-0002-1866-6885
0000-0003-0662-7704
0000-0003-4695-8620
0000-0002-9002-9880
0000-0002-8038-3341
0000-0003-2147-3555
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3349/ymj.2021.62.11.1016
PMID 34672135
PQID 2584799806
PQPubID 23479
PageCount 7
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_9872600
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8542470
proquest_miscellaneous_2584799806
pubmed_primary_34672135
crossref_citationtrail_10_3349_ymj_2021_62_11_1016
crossref_primary_10_3349_ymj_2021_62_11_1016
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-11-01
PublicationDateYYYYMMDD 2021-11-01
PublicationDate_xml – month: 11
  year: 2021
  text: 2021-11-01
  day: 01
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Yonsei medical journal
PublicationTitleAlternate Yonsei Med J
PublicationYear 2021
Publisher Yonsei University College of Medicine
연세대학교의과대학
Publisher_xml – name: Yonsei University College of Medicine
– name: 연세대학교의과대학
References Mukhtyar (10.3349/ymj.2021.62.11.1016_ref11) 2009; 68
Peng (10.3349/ymj.2021.62.11.1016_ref15) 2019; 11
Rodríguez-Rivera (10.3349/ymj.2021.62.11.1016_ref1) 2021; 134
Jennette (10.3349/ymj.2021.62.11.1016_ref7) 2014; 10
Watts (10.3349/ymj.2021.62.11.1016_ref6) 2007; 66
Abdallah (10.3349/ymj.2021.62.11.1016_ref14) 2018; 110
Stone (10.3349/ymj.2021.62.11.1016_ref20) 2010; 363
Choi (10.3349/ymj.2021.62.11.1016_ref8) 2017; 28
Bhamra (10.3349/ymj.2021.62.11.1016_ref13) 2012; 14
Park (10.3349/ymj.2021.62.11.1016_ref23) 2006; 7
Newkirk (10.3349/ymj.2021.62.11.1016_ref4) 1999; 26
Choi (10.3349/ymj.2021.62.11.1016_ref21) 2019; 60
Monach (10.3349/ymj.2021.62.11.1016_ref9) 2013; 72
Han (10.3349/ymj.2021.62.11.1016_ref10) 2004; 203
Jayne (10.3349/ymj.2021.62.11.1016_ref22) 2017; 28
Jennette (10.3349/ymj.2021.62.11.1016_ref5) 2013; 65
Agrawal (10.3349/ymj.2021.62.11.1016_ref16) 2003; 108
Correa-Rotter (10.3349/ymj.2021.62.11.1016_ref18) 1992; 3
Weng (10.3349/ymj.2021.62.11.1016_ref17) 2021; 99
Chen (10.3349/ymj.2021.62.11.1016_ref19) 2017; 13
Devauchelle (10.3349/ymj.2021.62.11.1016_ref3) 2006; 177
Guillevin (10.3349/ymj.2021.62.11.1016_ref12) 2011; 90
Falgarone (10.3349/ymj.2021.62.11.1016_ref2) 2009; 104
References_xml – volume: 177
  start-page: 6471
  year: 2006
  ident: 10.3349/ymj.2021.62.11.1016_ref3
  publication-title: J Immunol
  doi: 10.4049/jimmunol.177.9.6471
– volume: 66
  start-page: 222
  year: 2007
  ident: 10.3349/ymj.2021.62.11.1016_ref6
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2006.054593
– volume: 68
  start-page: 1827
  year: 2009
  ident: 10.3349/ymj.2021.62.11.1016_ref11
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2008.101279
– volume: 203
  start-page: 189
  year: 2004
  ident: 10.3349/ymj.2021.62.11.1016_ref10
  publication-title: Tohoku J Exp Med
  doi: 10.1620/tjem.203.189
– volume: 7
  start-page: 661
  year: 2006
  ident: 10.3349/ymj.2021.62.11.1016_ref23
  publication-title: Curr Drug Targets
  doi: 10.2174/138945006777435317
– volume: 11
  start-page: 2405
  year: 2019
  ident: 10.3349/ymj.2021.62.11.1016_ref15
  publication-title: Cancer Manag Res
  doi: 10.2147/CMAR.S196273
– volume: 104
  start-page: 139
  year: 2009
  ident: 10.3349/ymj.2021.62.11.1016_ref2
  publication-title: Adv Cancer Res
  doi: 10.1016/S0065-230X(09)04008-1
– volume: 65
  start-page: 1
  year: 2013
  ident: 10.3349/ymj.2021.62.11.1016_ref5
  publication-title: Arthritis Rheum
  doi: 10.1002/art.37715
– volume: 90
  start-page: 19
  year: 2011
  ident: 10.3349/ymj.2021.62.11.1016_ref12
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0b013e318205a4c6
– volume: 3
  start-page: 1172
  year: 1992
  ident: 10.3349/ymj.2021.62.11.1016_ref18
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.V351172
– volume: 26
  start-page: 597
  year: 1999
  ident: 10.3349/ymj.2021.62.11.1016_ref4
  publication-title: J Rheumatol
– volume: 60
  start-page: 705
  year: 2019
  ident: 10.3349/ymj.2021.62.11.1016_ref21
  publication-title: Yonsei Med J
  doi: 10.3349/ymj.2019.60.8.705
– volume: 14
  start-page: 494
  year: 2012
  ident: 10.3349/ymj.2021.62.11.1016_ref13
  publication-title: Curr Rheumatol Rep
  doi: 10.1007/s11926-012-0291-1
– volume: 110
  start-page: 221
  year: 2018
  ident: 10.3349/ymj.2021.62.11.1016_ref14
  publication-title: Bone
  doi: 10.1016/j.bone.2018.02.018
– volume: 108
  start-page: 539
  year: 2003
  ident: 10.3349/ymj.2021.62.11.1016_ref16
  publication-title: Immunology
  doi: 10.1046/j.1365-2567.2003.01608.x
– volume: 134
  start-page: 111174
  year: 2021
  ident: 10.3349/ymj.2021.62.11.1016_ref1
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2020.111174
– volume: 28
  start-page: 2756
  year: 2017
  ident: 10.3349/ymj.2021.62.11.1016_ref22
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2016111179
– volume: 28
  start-page: 3191
  year: 2017
  ident: 10.3349/ymj.2021.62.11.1016_ref8
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2016060690
– volume: 13
  start-page: 359
  year: 2017
  ident: 10.3349/ymj.2021.62.11.1016_ref19
  publication-title: Nat Rev Nephrol
  doi: 10.1038/nrneph.2017.37
– volume: 72
  start-page: 1342
  year: 2013
  ident: 10.3349/ymj.2021.62.11.1016_ref9
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2012-201981
– volume: 99
  start-page: 274
  year: 2021
  ident: 10.3349/ymj.2021.62.11.1016_ref17
  publication-title: Immunol Cell Biol
  doi: 10.1111/imcb.12405
– volume: 10
  start-page: 463
  year: 2014
  ident: 10.3349/ymj.2021.62.11.1016_ref7
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/nrrheum.2014.103
– volume: 363
  start-page: 221
  year: 2010
  ident: 10.3349/ymj.2021.62.11.1016_ref20
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0909905
SSID ssj0027102
Score 2.3132765
Snippet We investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-specific...
Purpose: We investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1016
SubjectTerms Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Antibodies, Antineutrophil Cytoplasmic
Blood Sedimentation
Clusterin - blood
Humans
Male
Middle Aged
Original
의학일반
Title Serum Clusterin Level Could Reflect the Current Activity of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
URI https://www.ncbi.nlm.nih.gov/pubmed/34672135
https://www.proquest.com/docview/2584799806
https://pubmed.ncbi.nlm.nih.gov/PMC8542470
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002766533
Volume 62
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Yonsei Medical Journal, 2021, 62(11), , pp.1016-1022
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1db9MwFLXWISFeEOOzjFUG8UhG7SS28zChqmIaiPGAKOzNij-yhbVJlyUS_fe7N0kLRQOJl0RK7FjxtXPuia_PJeQ1E8J6J2wQMQeHcWKCFOcVONfWAV7i3kmMtvgsTmbRx7P4bIess6L2HXh9K7XDfFKzan7482r1Dib8ETLOMErerhY_gOhxdig4fAFaPjogdwCaBLKx00j9YmCsDUKEgRgGuAmzkyH620O2oGpQVNltXuifwZS_odPxA3K_dyvppBsHe2THFw_J3dN-4fwRaeCb0CzodN6gMEJe0E8YLESnmOCafvEZ_ryn4AvSXq-JTmyXVoKWGZ1gNgnf1FW5vMih0qoul-B0L3Lb3jKlWwVrM3tHv7XBraiV9JjMjt9_nZ4EfcaFwIJjUgdGWeksNz7KlAQgBwB1sbcyMQZwDJgJuDuGxSbjziVeJArQzMtQyjFLWaxY-ITsFmXhnxGa4goxV8om3EaGxyb1UEgYJ4xHCZwh4evO1baXI8esGHMNtAQtosEiGi2iBQee0saiDcmbTaVlp8bx7-KvwGr60uYaVbTxfF7qy0oDV_igEyVRnX9IXq6NqmFq4XpJWviyudYcl5CBjo7hQU87I29aDQFgOAvjIZFb5t8UwAa37xT5RSvfreKIR3L8_P_eZZ_cwyvdNsgXZLeuGn8A_lBtRmQQB99H7d-EUTvebwCf8Qjd
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+Clusterin+Level+Could+Reflect+the+Current+Activity+of+Antineutrophil+Cytoplasmic+Antibody-Associated+Vasculitis&rft.jtitle=Yonsei+medical+journal&rft.au=Yoon%2C+Taejun&rft.au=Ahn%2C+Sung+Soo&rft.au=Pyo%2C+Jung+Yoon&rft.au=Song%2C+Jason+Jungsik&rft.date=2021-11-01&rft.issn=0513-5796&rft.eissn=1976-2437&rft.volume=62&rft.issue=11&rft.spage=1016&rft_id=info:doi/10.3349%2Fymj.2021.62.11.1016&rft.externalDBID=n%2Fa&rft.externalDocID=10_3349_ymj_2021_62_11_1016
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0513-5796&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0513-5796&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0513-5796&client=summon